Clinical Trial Update: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Onartuzumab in combination with mFOLFOX6 for metastatic HER2-negative, MET-positive gastric/gastroesophageal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Onartuzumab (onartuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Gastric Cancer | Phase 3 | Status: COMPLETED